About VectivBio
VectivBio is a company based in Basel (Switzerland) founded in 2019 was acquired by Ironwood Pharma in May 2023.. VectivBio has raised $145 million across 3 funding rounds from investors including Ironwood Pharma, TD Securities and Citadel. VectivBio has completed 1 acquisition, including Comet Therapeutics. VectivBio offers products and services including LINZESS and Pipeline Products. VectivBio operates in a competitive market with competitors including Phathom Pharmaceuticals, Guangzhou Zhiyi Pharmaceutics, Lumena Pharma, Palisade Bio and Kamui Pharma, among others.
- Headquarter Basel, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$145 M (USD)
in 3 rounds
-
Latest Funding Round
$54 M (USD), Post-IPO
Jul 06, 2022
-
Investors
Ironwood Pharma
& 11 more
-
Employee Count
Employee Count
- Investments & Acquisitions
-
Acquired by
Ironwood Pharma
(May 21, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VectivBio
VectivBio offers a comprehensive portfolio of products and services, including LINZESS and Pipeline Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats irritable bowel syndrome and chronic constipation.
Advances new therapies for gastrointestinal conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of VectivBio
VectivBio has successfully raised a total of $145M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $54 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $54.0M
-
First Round
First Round
(07 Jan 2020)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2022 | Amount | Post-IPO - VectivBio | Valuation |
investors |
|
| Oct, 2020 | Amount | Series D - VectivBio | Valuation | Citadel , Cormorant Capital | |
| Jan, 2020 | Amount | Series C - VectivBio | Valuation | Versant Ventures , Orbimed |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in VectivBio
VectivBio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Ironwood Pharma, TD Securities and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by VectivBio
VectivBio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Comet Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Enzyme substitution therapy for neurological diseases is developed.
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - VectivBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vectivbio Comparisons
Competitors of VectivBio
VectivBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Phathom Pharmaceuticals, Guangzhou Zhiyi Pharmaceutics, Lumena Pharma, Palisade Bio and Kamui Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Second-generation probiotics are developed for gastrointestinal disorders.
|
|
| domain | founded_year | HQ Location |
Passionately pursuing better treatments for adults and children with rare liver diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal complications are developed by Palisade Bio.
|
|
| domain | founded_year | HQ Location |
Probiotic medicines for treating gastrointestinal diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vectivbio
Frequently Asked Questions about VectivBio
When was VectivBio founded?
VectivBio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is VectivBio located?
VectivBio is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Is VectivBio a funded company?
VectivBio is a funded company, having raised a total of $145M across 3 funding rounds to date. The company's 1st funding round was a Series C of $35M, raised on Jan 07, 2020.
What does VectivBio do?
Developer of transformative therapeutics for rare diseases The lead product is Apraglutide which is a synthetic GLP-2 analog for the treatment of short bowel syndrome. It is designed to increase the intestines ability to absorb fluid and nutrients to minimize parenteral support and improve patient health.
Who are the top competitors of VectivBio?
VectivBio's top competitors include Phathom Pharmaceuticals, Palisade Bio and Lumena Pharma.
What products or services does VectivBio offer?
VectivBio offers LINZESS and Pipeline Products.
How many acquisitions has VectivBio made?
VectivBio has made 1 acquisition, including Comet Therapeutics.
Who are VectivBio's investors?
VectivBio has 12 investors. Key investors include Ironwood Pharma, TD Securities, Citadel, Orbimed, and Bpifrance.